Shengdi Chen, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China
koto_feja / Getty Images / iStock
Articles
-
-
Maintaining the balance of TDP-43, mitochondria, and autophagy: a promising therapeutic strategy for neurodegenerative diseases
-
Precision medicine in Parkinson’s disease patients with LRRK2 and GBA risk variants – Let’s get even more personal
-
Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance
-
Exploring the regulatory roles of circular RNAs in Alzheimer’s disease
Editor-in-Chief
Aims and Scope
Translational Neurodegeneration is an open access, peer-reviewed journal that covers research, therapeutics and education for all aspects of neurodegenerative diseases. By offering a high-visibility forum for new insights and discussions, Translational Neurodegeneration creates a novel interface between the fields of basic, translational, and clinical research. It includes Parkinson's disease and movement disorders, Alzheimer's disease and other dementias, motor neuron disease and other neurodegenerative diseases.
Announcing the launch of In Review
Translational Neurodegeneration, in partnership with Research Square, is now offering In Review. Authors choosing this free optional service will be able to:
- Share their work with fellow researchers to read, comment on, and cite even before publication
- Showcase their work to funders and others with a citable DOI while it is still under review
- Track their manuscript - including seeing when reviewers are invited, and when reports are received
Affiliated with
Annual Journal Metrics
-
Speed
62 days to first decision for reviewed manuscripts only
29 days to first decision for all manuscripts
158 days from submission to acceptance
28 days from acceptance to publicationCitation Impact
5.551 - 2-year Impact Factor
1.454 - Source Normalized Impact per Paper (SNIP)
1.812 - SCImago Journal Rank (SJR)Usage
239,958 Downloads
168 Altmetric Mentions
